Deruxtecan analog(MC-GGFG-Exetecan) CAS:1599440-13-7 is a cutting-edge drug-linker conjugate designed for the development of antibody-drug conjugates (ADCs). This unique compound, derived from exatecan (DX-8951), features a topoisomerase I inhibitor, a cleavable peptide linker, and a maleimide group, offering enhanced stability and selectivity for targeted therapies.
Introduction to the application:
Deruxtecan analog plays a vital role in the creation of innovative ADCs, such as Trastuzumab deruxtecan (DS-8201a), a HER2-targeting therapy. The maleimide group enables the formation of ADCs by reacting with antibodies, resulting in treatments with profound antitumor effects. DS-8201a has demonstrated significant tumor suppression in preclinical studies and is currently under evaluation in clinical trials, showcasing its potential in advancing cancer treatment options.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
